NCT04573946View on ClinicalTrials.gov

VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)

NAActive, not recruitingINTERVENTIONAL
Enrollment

25,871

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

July 21, 2023

Study Completion Date

December 31, 2025

Conditions
Bone DensityBone HealthFractures
Interventions
DIETARY_SUPPLEMENT

Vitamin D3 placebo

Vitamin D placebo

DIETARY_SUPPLEMENT

Fish oil placebo

Fish oil placebo

DRUG

Omega-3 fatty acids (fish oil)

Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

DIETARY_SUPPLEMENT

Vitamin D3

"Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol"

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT04573946 - VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL) | Biotech Hunter | Biotech Hunter